Narayana A, Mathew M, Tam M, Kannan R, et al. J Neurooncol. Apr 12, 2013.
“Brain metastases in malignant melanoma carries a poor prognosis with minimal response to any therapy. The purpose of this pilot analysis was to find the effectiveness of vemurafenib, an oral BRAF inhibitor, and radiation therapy in V600 mutated melanoma with brain metastases. BRAF mutation status of the melanoma patients was determined by real-time PCR assay…”
Sun Y, Nowak KA ... Dicker AP, Lu B, Mol Cancer Ther, Feb 26, 2013
Crizotinib (PF02341066) is a tyrosine kinase inhibitor of ALK that has been shown to selectively inhibit growth of cancer cells that harbor the EML4-ALK fusion, found in a subset of patients with non-small cell lung cancer (NSCLC). Our current findings indicate that PF02341066 acts as a radiation sensitizer in cells harboring the EML4-ALK fusion, providing a rationale for a clinical trial combining ALK inhibitor with radiation in the NSCLC expressing ALK.
Results of a clinical trial that evaluated the prostate cancer vaccine Provenge have come under scrutiny. Questions arise regarding the reported 4-month survival benefit that ultimately led to FDA approval. Disputers suggest that a flaw in methods led to the survival benefit, but that the vaccine may actually cause harm.
A recent study evaluated the usefulness of surgery versus observation to treat localized prostate cancer. In the study, 731 men were followed for 10 years. Those treated with surgery did not have a significant decreased risk of death compared to those who were observed for advancing cancer.
A recent study weighed the benefits of yearly prostate cancer screening, finding that the potential disadvantages decrease the potential advantages by 23%. Harmful results of yearly prostate screening include negative prostate biopsies, radical prostatectomy, and radiation therapy.
A recent study found a relationship between the SPARCL1 gene and prostate cancer recurrence. Individuals who had lower activity of the gene had a higher risk of prostate cancer recurrence over 10 years. A test to detect SPARCL1 is being designed.
The New England Journal of Medicine | Oct 25, 2012
The utility of (prostate-specific antigen) PSA screening to inform prostate cancer diagnosis and treatment has been a topic of heated debate. The New England Journal of Medicine (NEJM) conducted a poll that indicates a lack of consensus among clinicians regarding best prostate cancer screening practices. Many clinicians feel patients should make informed decisions regarding testing preferences.
The FDA has approved enzalutamide (sold as Xtandi) 3 months ahead of deadline. The drug improved survival by nearly 5 months in men with advanced prostate cancer. It is approved for individuals who have not responded to chemotherapy. However, manufacturers hope to expand approval to include patients not previously treated with chemotherapy.
A recent study evaluated androgen deprivation therapy with and without radiation therapy in individuals with locally advanced prostate cancer. Individuals who received combination treatment had a better overall survival rate. Bowel-related side effects were similar for both groups 24 months after treatment.